LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 07:00:00 CEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
Bringg Welcomes Chris Conway as Senior Vice President and General Manager, EMEA21.4.2026 07:00:00 CEST | Press release
Conway, who scaled one of the UK’s largest delivery operations as a Bringg customer, joins to lead the company’s European expansion Bringg, the last-mile performance leader, today announced Chris Conway's appointment as Senior Vice President and General Manager, EMEA. Conway will lead Bringg's commercial strategy, customer relationships, and go-to-market operations across the region. Conway brings more than 20 years of experience in eCommerce, digital commerce, and operational transformation at three of the UK's largest grocery retailers. Most recently, he served as Managing Director of Quick Commerce and Food Operating Board Member at Co-op, where he built and scaled a £500 million-plus q-commerce operation delivering from nearly 2,000 stores. He also founded Peckish, a rapid delivery app that gave independent retailers access to q-commerce technology. He also led Asda's online grocery business to more than £1 billion in revenue and 20% market share, and ran the online commercial team
Edge Home Finance Announces Strategic Investment from Presidio Investors and Promotion of Tom Ahles to President21.4.2026 06:06:00 CEST | Press release
Edge Home Finance today announced a strategic investment from Presidio Investors (“Presidio”), marking a major milestone in the company’s continued expansion and leadership within the mortgage broker channel. As part of this transaction, Tom Ahles has been promoted to President of Edge Home Finance, reinforcing the company’s commitment to strong leadership as it enters its next phase of growth. The investment from Presidio represents a powerful alignment focused on accelerating Edge’s momentum through enhanced investment in technology, operational infrastructure, and strategic acquisitions. Presidio brings a track record of partnering with high-growth companies and scaling them through disciplined capital deployment and operational expertise. “This strategic investment is a direct reflection of the strength of our platform and the momentum we’ve built,” said Tom Ahles, President of Edge Home Finance. “With Presidio’s backing, we are positioned to move faster, invest more aggressively i
JPMorganChase Expands Security and Resiliency Initiative Across Europe21.4.2026 06:00:00 CEST | Press release
Broader geographic focus builds on momentum in the U.S. and reinforces commitment to strengthening critical supply chains, economic resilience and shared security across trading partners JPMorganChase today announced the expansion of its $1.5 trillion, 10-year Security and Resiliency Initiative (SRI) — which seeks to facilitate, finance and invest in industries vital to economic security — across Europe. Building on the initiative’s momentum in the U.S. and previously announced intention to expand to the U.K., the announcement underscores JPMorganChase’s commitment to strengthening supply chains and supporting industries critical to innovation and growth. “The national and economic security of countries depends on strong, resilient and reliable supply chains, and robust critical industries,” said Jamie Dimon, Chairman and CEO of JPMorganChase. “For too long, the U.S. and Europe have relied on unpredictable sources for things like critical minerals that are essential to collective secur
Presidio Investors Expands Portfolio with Strategic Investment in Edge Home Finance21.4.2026 03:10:00 CEST | Press release
Presidio Investors ("Presidio") has completed a strategic investment in Edge Home Finance, a mortgage brokerage platform. Headquartered in Minnetonka, MN, Edge Home Finance has built a strong reputation within the mortgage broker channel by empowering loan originators and delivering best-in-class service and innovation. The investment from Presidio represents an opportunity to leverage Edge’s momentum through enhanced investments in technology, operational infrastructure, and strategic acquisitions. Edge Home Finance will continue operating with the same core platform, team, and commitment to the broker community that has fueled its success. Partner, Victor Masaya, of Presidio Investors, commented: “Edge Home Finance's platform, track record and broker-focused approach aligns perfectly with our vision of fostering excellence and growth. Together, we aim to redefine what's possible in the mortgage brokerage channel and deliver an unparalleled value proposition to loan originators." Edge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom